Yifan Pharmaceutical Co., Ltd. (002019.SZ)
CNY 11.38
(0.53%)
CNY 11.38
(0.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.99 Billion CNY | -7.72% |
| 2022 | 2.16 Billion CNY | -4.3% |
| 2021 | 2.25 Billion CNY | 36.19% |
| 2020 | 1.65 Billion CNY | -13.18% |
| 2019 | 1.91 Billion CNY | 27.68% |
| 2018 | 1.49 Billion CNY | 40.84% |
| 2017 | 1.06 Billion CNY | -31.91% |
| 2016 | 1.56 Billion CNY | 103.5% |
| 2015 | 766.85 Million CNY | 162.15% |
| 2014 | 292.52 Million CNY | -29.79% |
| 2013 | 416.67 Million CNY | -8.56% |
| 2012 | 455.65 Million CNY | -16.55% |
| 2011 | 546 Million CNY | 26.98% |
| 2010 | 430 Million CNY | 152.94% |
| 2009 | 170 Million CNY | -24.44% |
| 2008 | 225 Million CNY | 7.66% |
| 2007 | 209 Million CNY | -4.13% |
| 2006 | 218 Million CNY | 52.45% |
| 2005 | 143 Million CNY | 521.74% |
| 2004 | 23 Million CNY | -71.39% |
| 2003 | 80.38 Million CNY | 81.12% |
| 2002 | 44.38 Million CNY | 51.06% |
| 2001 | 29.38 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.2 Billion CNY | 9.76% |
| 2024 Q1 | 2.01 Billion CNY | 0.86% |
| 2024 Q3 | 2.45 Billion CNY | -19.95% |
| 2023 FY | 1.99 Billion CNY | -7.72% |
| 2023 Q2 | 2.12 Billion CNY | -8.41% |
| 2023 Q3 | 1.92 Billion CNY | -9.29% |
| 2023 Q4 | 1.99 Billion CNY | 3.64% |
| 2023 Q1 | 2.31 Billion CNY | 7.18% |
| 2022 Q1 | 2.64 Billion CNY | 17.01% |
| 2022 Q3 | 2.52 Billion CNY | -3.53% |
| 2022 FY | 2.16 Billion CNY | -4.3% |
| 2022 Q2 | 2.61 Billion CNY | -0.91% |
| 2022 Q4 | 2.16 Billion CNY | -14.44% |
| 2021 Q1 | 1.99 Billion CNY | 20.02% |
| 2021 Q4 | 2.25 Billion CNY | 11.27% |
| 2021 FY | 2.25 Billion CNY | 36.19% |
| 2021 Q2 | 2.01 Billion CNY | 1.27% |
| 2021 Q3 | 2.03 Billion CNY | 0.69% |
| 2020 Q3 | 2.04 Billion CNY | 1.17% |
| 2020 Q1 | 2.12 Billion CNY | 11.17% |
| 2020 FY | 1.65 Billion CNY | -13.18% |
| 2020 Q2 | 2.02 Billion CNY | -4.89% |
| 2020 Q4 | 1.65 Billion CNY | -18.84% |
| 2019 Q4 | 1.91 Billion CNY | 16.76% |
| 2019 Q3 | 1.63 Billion CNY | -7.14% |
| 2019 FY | 1.91 Billion CNY | 27.68% |
| 2019 Q1 | 1.62 Billion CNY | 8.35% |
| 2019 Q2 | 1.76 Billion CNY | 8.68% |
| 2018 Q4 | 1.49 Billion CNY | 12.89% |
| 2018 Q1 | 1.1 Billion CNY | 3.55% |
| 2018 FY | 1.49 Billion CNY | 40.84% |
| 2018 Q2 | 1.11 Billion CNY | 1.77% |
| 2018 Q3 | 1.32 Billion CNY | 18.38% |
| 2017 FY | 1.06 Billion CNY | -31.91% |
| 2017 Q3 | 1.3 Billion CNY | -23.12% |
| 2017 Q2 | 1.69 Billion CNY | -0.07% |
| 2017 Q1 | 1.69 Billion CNY | 8.53% |
| 2017 Q4 | 1.06 Billion CNY | -18.33% |
| 2016 FY | 1.56 Billion CNY | 103.5% |
| 2016 Q1 | 847.02 Million CNY | 10.45% |
| 2016 Q2 | 1.44 Billion CNY | 70.46% |
| 2016 Q4 | 1.56 Billion CNY | -0.06% |
| 2016 Q3 | 1.56 Billion CNY | 8.15% |
| 2015 Q4 | 766.85 Million CNY | 58.42% |
| 2015 Q3 | 484.05 Million CNY | -9.1% |
| 2015 Q2 | 532.49 Million CNY | 102.74% |
| 2015 Q1 | 262.64 Million CNY | -10.22% |
| 2015 FY | 766.85 Million CNY | 162.15% |
| 2014 Q4 | 292.52 Million CNY | -1.71% |
| 2014 Q3 | 297.6 Million CNY | -18.58% |
| 2014 Q1 | 407 Million CNY | -2.32% |
| 2014 Q2 | 365.5 Million CNY | -10.2% |
| 2014 FY | 292.52 Million CNY | -29.79% |
| 2013 FY | 416.67 Million CNY | -8.56% |
| 2013 Q4 | 416.67 Million CNY | -1.28% |
| 2013 Q3 | 422.06 Million CNY | -6.76% |
| 2013 Q2 | 452.65 Million CNY | -5.42% |
| 2013 Q1 | 478.58 Million CNY | 5.03% |
| 2012 FY | 455.65 Million CNY | -16.55% |
| 2012 Q2 | 430 Million CNY | -18.56% |
| 2012 Q4 | 455.65 Million CNY | 8.1% |
| 2012 Q3 | 421.5 Million CNY | -1.98% |
| 2012 Q1 | 528 Million CNY | -3.3% |
| 2011 Q2 | 499.94 Million CNY | 2.82% |
| 2011 Q4 | 546 Million CNY | 9.65% |
| 2011 Q3 | 497.94 Million CNY | -0.4% |
| 2011 Q1 | 486.23 Million CNY | 13.08% |
| 2011 FY | 546 Million CNY | 26.98% |
| 2010 Q2 | 350 Million CNY | 59.09% |
| 2010 Q4 | 430 Million CNY | 10.26% |
| 2010 Q3 | 390 Million CNY | 11.43% |
| 2010 FY | 430 Million CNY | 152.94% |
| 2010 Q1 | 220 Million CNY | 29.41% |
| 2009 Q1 | 245 Million CNY | 8.89% |
| 2009 Q4 | 170 Million CNY | -38.18% |
| 2009 FY | 170 Million CNY | -24.44% |
| 2009 Q2 | 255 Million CNY | 4.08% |
| 2009 Q3 | 275 Million CNY | 7.84% |
| 2008 FY | 225 Million CNY | 7.66% |
| 2008 Q3 | 215 Million CNY | 19.44% |
| 2008 Q2 | 180 Million CNY | 0.0% |
| 2008 Q1 | 180 Million CNY | -13.88% |
| 2008 Q4 | 225 Million CNY | 4.65% |
| 2007 Q2 | 226 Million CNY | 17.1% |
| 2007 Q1 | 193 Million CNY | -11.47% |
| 2007 Q3 | 219 Million CNY | -3.1% |
| 2007 Q4 | 209 Million CNY | -4.57% |
| 2007 FY | 209 Million CNY | -4.13% |
| 2006 Q1 | 148 Million CNY | 3.5% |
| 2006 Q3 | 177 Million CNY | 9.26% |
| 2006 FY | 218 Million CNY | 52.45% |
| 2006 Q4 | 218 Million CNY | 23.16% |
| 2006 Q2 | 162 Million CNY | 9.46% |
| 2005 FY | 143 Million CNY | 521.74% |
| 2005 Q1 | 78 Million CNY | 239.13% |
| 2005 Q2 | 130 Million CNY | 66.67% |
| 2005 Q3 | 138 Million CNY | 6.15% |
| 2005 Q4 | 143 Million CNY | 3.62% |
| 2004 FY | 23 Million CNY | -71.39% |
| 2004 Q3 | 29.82 Million CNY | -66.94% |
| 2004 Q2 | 90.2 Million CNY | 0.0% |
| 2004 Q4 | 23 Million CNY | -22.89% |
| 2003 FY | 80.38 Million CNY | 81.12% |
| 2003 Q4 | 80.38 Million CNY | 0.0% |
| 2002 FY | 44.38 Million CNY | 51.06% |
| 2001 FY | 29.38 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 2.54 Billion CNY | 21.542% |
| Zhejiang Zhenyuan Share Co., Ltd. | 138.12 Million CNY | -1344.431% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 593.88 Million CNY | -235.958% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 935.85 Million CNY | -113.193% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 4.36 Million CNY | -45601.401% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 7.55 Billion CNY | 73.595% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 273.99 Million CNY | -628.175% |
| Boai NKY Medical Holdings Ltd. | 60.4 Million CNY | -3202.848% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 62.44 Million CNY | -3095.216% |